Cullinan Therapeutics Inc
CGEMHealthcare|Biotechnology|USA
$18.13
-0.24 (-1.31%)
Tangible Book
$5.96
Earnings Power
$7.63
Upcoming Data Readouts (6)
Sep 2026
Est. completion
P1Multiple Myeloma
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141n=30
Nov 2026
Est. completion
P1NHL
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
NCT05879744n=90
Dec 2026
Est. completion
P1SLE
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360n=24
Jan 2027
Est. completion
P1Relapsed/Refractory Acute Myeloid Leukemia (AML)
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT05143996n=60
Dec 2027
Est. completion
P1Rheumatoid Arthritis (RA
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
NCT06994143n=37
Mar 2028
Est. completion
P1Sjögren
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099n=36
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P1
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476